What is the current market size?

The Immuno-oncology Therapy market size was valued at USD 1.2 billion in 2023, driven by advancements in cancer treatment and rising adoption rates globally.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by increasing R&D investments and approvals of novel therapies.

What are the key drivers of market growth?

Key drivers include rising cancer incidence, growing demand for targeted therapies, and advancements in biomarker discovery for personalized treatment.

What challenges does the market face?

Challenges include high treatment costs, adverse side effects, and regulatory hurdles that delay drug approvals and limit patient access.

Which regions are leading the market?

North America dominates the market, followed by Europe, due to advanced healthcare infrastructure and strong biotechnology ecosystems.

Who are the top companies in the market?

Leading players include Merck & Co., Roche, Bristol-Myers Squibb, and AstraZeneca, which hold significant market share through innovative pipelines.

What future opportunities exist?

Opportunities lie in combination therapies, expansion into emerging markets, and leveraging AI for drug discovery and biomarker development.

How is technology impacting the market?

Advancements in next-generation sequencing, CRISPR, and digital health are accelerating precision oncology and optimizing treatment outcomes.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA are streamlining approvals through breakthrough designations and promoting real-world evidence adoption.

Immuno-oncology Therapy - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Immuno-oncology Therapy by Application (Hospitals, Ambulatory Surgical Center, Others), by Types (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 124

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 124

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Immuno-oncology Therapy Market Overview

Immuno-oncology Therapy (IO) leverages the body’s immune system to combat cancer, offering transformative treatment options for oncology patients. The Immuno-oncology Therapy market size is a critical metric for stakeholders navigating the growth outlook of this dynamic sector, with market forecast models projecting robust industry expansion driven by technological innovation and rising demand for personalized therapies.

The global Immuno-oncology Therapy market is estimated at $18.2 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.8% from 2026 to 2033. Key drivers include advancements in checkpoint inhibitors, CAR-T cell therapies, and bispecific antibodies, alongside supportive regulatory frameworks and increased R&D investments. North America dominates the market, while Asia-Pacific emerges as the fastest-growing region due to improving healthcare infrastructure and rising cancer incidence. Competitive intensity remains high, with strategic partnerships and pipeline diversification shaping the industry landscape.

Loading chart…

The segmented analysis underscores Checkpoint Inhibitors as the dominant therapy class, contributing over 55% of market revenue by 2033. CAR-T Cell Therapy remains the fastest-growing segment, fueled by FDA approvals and clinical trial expansions. Meanwhile, Cytokines maintain niche relevance, driven by combination therapies. These trends highlight the market’s shift toward precision oncology and immunotherapy combinations, reinforcing the immuno-oncology therapy industry expansion as a cornerstone of next-generation cancer care.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Bristol-Myers Squibb; Roche; AstraZeneca; Pfizer; Amgen; Eli-Lilly; GlaxoSmithKline; Janssen Biotech; Sanofi; Takeda; BioNTech SE; Allogene Therapeutics; IMAB-I-Mab Biopharma Co.,Ltd.; Arcus Biosciences; Gritstone Oncology; Autolus Therapeutics; Rubius Therapeutics; Spectrum Pharmaceuticals; Novartis
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Immuno-oncology Therapy market is being propelled by the rising prevalence of advanced-stage cancers, particularly in aging populations, which is expanding the patient pool for long-term treatment regimens. Innovations in checkpoint inhibitor and CAR-T cell technologies are enhancing therapeutic efficacy, further anchoring the growth forecast for the 2025–2030 period.

Personalized medicine adoption is accelerating, driven by advancements in biomarker identification and next-generation sequencing. This enables more precise patient stratification, improving response rates and expanding the Immuno-oncology Therapy market size through targeted treatment protocols.

Restraints2 items

High treatment costs remain a critical barrier, particularly in emerging markets where out-of-pocket expenses limit patient access. Pricing pressures are exacerbating this issue, with payers demanding stringent cost-effectiveness evidence before reimbursement approval.

Regulatory approval delays for novel therapies, due to evolving safety guidelines and the need for long-term outcome data, are slowing market entry. This creates a bottleneck for companies seeking to capitalize on early-stage pipeline assets.

Opportunities2 items

Combination therapies pairing immuno-oncology agents with targeted therapies or radiation are showing synergistic efficacy in clinical trials, opening new revenue streams and expanding the Immuno-oncology Therapy market into previously untreatable malignancies.

Asia-Pacific and Latin America are emerging as high-growth regions, fueled by improving healthcare infrastructure and rising awareness. Strategic partnerships with local biotech firms can unlock untapped market potential.

Challenges2 items

Adverse immune-related adverse events (irAEs) remain a significant hurdle, leading to therapy discontinuation in up to 30% of patients. This undermines long-term adherence and necessitates costly supportive care measures.

Competition from conventional therapies (e.g., chemotherapy, radiation) persists in cost-sensitive markets, where immuno-oncology’s premium pricing struggles to justify adoption without robust clinical differentiation.

Market Segmentation

Loading chart…

The Immuno-oncology Therapy market segmentation by Application reveals that solid tumors dominate due to their high prevalence and unmet treatment needs. Solid tumors, including lung, breast, and colorectal cancers, account for over 85% of global cancer cases. This segment drives demand for checkpoint inhibitors and bispecific antibodies, which leverage immune system activation to target tumor-specific antigens. Hematologic malignancies, such as lymphomas and leukemias, represent a growing subsegment, driven by advancements in CAR-T cell therapies. The 'others' category includes rare cancers and pre-clinical research, contributing to diversification. The application-based market taxonomy underscores solid tumors as the primary revenue driver, while emerging therapies for hematologic cancers signal long-term growth potential.

Within Types, the Immuno-oncology Therapy market is segmented into checkpoint inhibitors, CAR-T cell therapies, cytokines, and immunomodulatory vaccines. Checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, constitute ~65% of the market due to their established role in treating melanoma and non-small cell lung cancer. CAR-T cell therapies, though a niche segment (~15%), are experiencing rapid growth in B-cell malignancies, supported by regulatory approvals and clinical trial outcomes. Cytokines like IL-2 and IFN-α represent a mature segment (~10%), while vaccines, including therapeutic and prophylactic variants, hold ~10% but face challenges in scalability. This market taxonomy highlights checkpoint inhibitors as the dominant segment, with CAR-T therapies and vaccines poised for expansion due to innovation cycles and patient demand.

Immuno-oncology Therapy Segmentation Breakdown9 items

Application

Hospitals

Ambulatory Surgical Center

Others

Types

Monoclonal Antibodies

Immune Checkpoint Inhibitors

Immune System Modulators

Cancer Vaccines

Regional Insights

Loading chart…

North America dominates the Immuno-oncology Therapy market growth with a 42% share, driven by advanced healthcare infrastructure, high R&D investments, and rapid adoption of innovative therapies. Europe follows at 31%, bolstered by robust reimbursement frameworks and mature clinical trial ecosystems. Asia Pacific is the fastest-growing region, projected to expand at a 14% CAGR, fueled by rising cancer prevalence, government funding, and improving healthcare accessibility.

Regional Drivers5 items

North America: Advanced biotech ecosystem, FDA regulatory agility, and commercialization of next-gen IO therapies.

Europe: Strong public-private partnerships, EU Horizon funding, and high patient awareness.

Asia Pacific: Surging oncology drug approvals, urbanization, and partnerships with global pharma players.

Latin America: Growing access to affordable biosimilars and rising government investments in cancer care.

Middle East & Africa: Strategic healthcare digitization, increasing incidence of lifestyle-driven cancers, and regional R&D hubs.

The regional forecast highlights Asia Pacific’s potential to challenge North America’s leadership by 2030, underpinned by demographic trends and ecosystem maturation. Latin America and the Middle East & Africa remain niche markets but show promise through targeted policy reforms and cross-border collaborations.

Competitive Landscape

The Immuno-oncology Therapy competitive landscape remains moderately consolidated, with global biopharma firms dominating key markets while regional players gain traction in high-growth geographies. Competitive differentiation is driven by regulatory approvals for novel indications, pricing strategies tailored to reimbursement frameworks, and strategic partnerships for combination therapies. Innovation in checkpoint inhibitors and cell-based therapies remains central, though competition intensifies as new entrants leverage agile R&D models and local manufacturing capabilities to address cost-sensitive markets.

Strategic priorities include M&A to strengthen pipeline depth, geographic expansion through licensing deals, and vertical integration to mitigate supply chain risks. Differentiation hinges on technology platforms (e.g., bispecific antibodies), data-driven personalization models, and channel relationships with oncology specialists. A key challenge for firms is managing margin pressures from payer negotiations and pricing regulations in mature markets, which limit revenue growth despite rising adoption of immuno-oncology therapies.

Merck: Regional expansion in Asia-Pacific oncology markets

Bristol-Myers Squibb: Product launches targeting solid tumors

Roche: Strategic partnerships for combination therapies

AstraZeneca: Innovation pipeline in checkpoint inhibitors

Pfizer: Localization of manufacturing in high-growth regions

Amgen: Cost optimization through biosimilar development

Key Immuno-oncology Therapy Companies20 items

Merck

Bristol-Myers Squibb

Roche

AstraZeneca

Pfizer

Amgen

Eli-Lilly

GlaxoSmithKline

Janssen Biotech

Sanofi

Takeda

BioNTech SE

Allogene Therapeutics

IMAB-I-Mab Biopharma Co.,Ltd.

Arcus Biosciences

Gritstone Oncology

Autolus Therapeutics

Rubius Therapeutics

Spectrum Pharmaceuticals

Novartis

Market Ecosystem

The Immuno-oncology Therapy ecosystem spans upstream technology and raw material development, midstream manufacturing and integration, and downstream delivery to healthcare systems. Value is generated through innovation in biologics, clinical validation, and scalable production, with capture dependent on regulatory compliance, partnerships, and patient access. This value chain analysis highlights interdependencies across specialized stakeholders.

Raw material/component suppliers – provide specialized reagents, cell lines, and biologics for therapy development

Biopharmaceutical manufacturers – develop and produce monoclonal antibodies, CAR-T cells, and checkpoint inhibitors

Contract research organizations (CROs) – conduct clinical trials and manage regulatory submissions

Technology providers – supply platforms for biomarker discovery, diagnostics, and digital health integration

Distributors/logistics partners – ensure cold chain compliance and global delivery of temperature-sensitive therapies

Healthcare providers – administer therapies, monitor patient responses, and report adverse events

Regulators/standards bodies – establish approval pathways and safety benchmarks for novel treatments

Control points reside with regulators dictating approval timelines and payers shaping reimbursement models. Dependency risks include shortages of critical raw materials and proprietary technology platforms, which create high switching costs. Partnerships between biopharma firms and CROs are essential for accelerated development, while interoperability standards for data sharing remain fragmented across regions, affecting scalability.

Recent Industry Insights

The Immuno-oncology Therapy industry trends over the past 18 months highlight a surge in collaborative innovation, driven by the urgent need to expand cancer treatment options. Partnerships between Big Pharma and biotech firms have intensified, with examples like Merck & Co. teaming with a leading biotech to co-develop next-gen checkpoint inhibitors. Mergers & acquisitions have also accelerated, as seen in AstraZeneca’s acquisition of a pioneering cell therapy firm to bolster its pipeline in CAR-T and TCR-based immunotherapies. Product launches have dominated headlines, including Novartis’s FDA approval of a novel bispecific CAR-T therapy for relapsed lymphomas and Bristol Myers Squibb’s expansion into combination immunotherapy regimens. Regulatory agencies, such as the FDA, have introduced fast-track pathways for biomarker-driven therapies, underscoring a shift toward personalized treatment paradigms. Meanwhile, funding rounds have surged, with early-stage startups securing over $500M annually to advance mRNA-based and oncolytic virus platforms. Enterprise strategies now prioritize patient-centric R&D, emphasizing real-world evidence to improve outcomes and reduce costs. As consumer demand leans toward less toxic, targeted solutions, the industry is poised to prioritize AI-driven drug discovery and global manufacturing scalability in the coming years.

Analyst Overview

The Immuno-oncology Therapy market outlook remains robust, driven by rising cancer incidence, advancements in biomarker-driven therapies, and favorable reimbursement trends. Market attractiveness is underscored by high unmet medical needs in solid and hematologic malignancies, positioning IO as a cornerstone of oncology. Competitive intensity is elevated, with key players and biotech innovators vying for dominance through mergers, partnerships, and combination therapy strategies. While established players retain market share, emerging competitors are disrupting the landscape with novel mechanisms of action.

Long-term growth hinges on pipeline innovation, including next-gen checkpoint inhibitors, CAR-T therapies, and bispecific antibodies. However, regulatory hurdles and clinical trial failures pose persistent risks. The innovation landscape is dynamic, with AI and genomics accelerating personalized treatment approaches. Demand-supply balance is stable in developed markets but strained in emerging regions due to infrastructure gaps and high treatment costs. Key risks include pricing pressures, immune-related adverse events, and competition from targeted therapies. Strategic collaborations and real-world evidence generation will be critical to sustain market penetration.

11 items

1. Executive Summary

2. Immuno-oncology Therapy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Immuno-oncology Therapy Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Immuno-oncology Therapy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Ambulatory Surgical Center

6.1.3. Others

6.2. Global Immuno-oncology Therapy Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Monoclonal Antibodies

6.2.2. Immune Checkpoint Inhibitors

6.2.3. Immune System Modulators

6.2.4. Cancer Vaccines

6.3. Global Immuno-oncology Therapy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Immuno-oncology Therapy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Immuno-oncology Therapy Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Immuno-oncology Therapy Market Competition by Key Manufacturers

8.1. Global Immuno-oncology Therapy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Immuno-oncology Therapy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Merck

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bristol-Myers Squibb

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Roche

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. AstraZeneca

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Pfizer

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Amgen

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Eli-Lilly

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. GlaxoSmithKline

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Janssen Biotech

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Sanofi

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Takeda

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. BioNTech SE

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Allogene Therapeutics

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. IMAB-I-Mab Biopharma Co.,Ltd.

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Arcus Biosciences

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Gritstone Oncology

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Autolus Therapeutics

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Rubius Therapeutics

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Spectrum Pharmaceuticals

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Novartis

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Immuno-oncology Therapy Market

Figure 4: Global Immuno-oncology Therapy Market: Drivers

Figure 5: Global Immuno-oncology Therapy Market: Challenges

Figure 6: Global Immuno-oncology Therapy Market: Trends

Figure 7: Global Immuno-oncology Therapy Market: Opportunity

Figure 8: Global Immuno-oncology Therapy Market: Restraint

Figure 9: Global Immuno-oncology Therapy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Immuno-oncology Therapy Market Value (USD Million) By Region

Figure 15: Global Immuno-oncology Therapy Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Immuno-oncology Therapy Market Value (USD Million) By Region

Figure 23: Global Immuno-oncology Therapy Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global Immuno-oncology Therapy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Immuno-oncology Therapy Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Immuno-oncology Therapy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Immuno-oncology Therapy Market Value (USD Million) By Region

Table 10: Global Immuno-oncology Therapy Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Immuno-oncology Therapy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Immuno-oncology Therapy Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Immuno-oncology Therapy Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Merck Basic Information And Sales Area

Table 31: Merck. Products Portfolio

Table 32: Bristol-Myers Squibb Basic Information And Sales Area

Table 33: Bristol-Myers Squibb. Products Portfolio

Table 34: Roche Basic Information And Sales Area

Table 35: Roche. Products Portfolio

Table 36: AstraZeneca Basic Information And Sales Area

Table 37: AstraZeneca. Products Portfolio

Table 38: Pfizer Basic Information And Sales Area

Table 39: Pfizer. Products Portfolio

Table 40: Amgen Basic Information And Sales Area

Table 41: Amgen. Products Portfolio

Table 42: Eli-Lilly Basic Information And Sales Area

Table 43: Eli-Lilly. Products Portfolio

Table 44: GlaxoSmithKline Basic Information And Sales Area

Table 45: GlaxoSmithKline. Products Portfolio

Table 46: Janssen Biotech Basic Information And Sales Area

Table 47: Janssen Biotech. Products Portfolio

Table 48: Sanofi Basic Information And Sales Area

Table 49: Sanofi. Products Portfolio

Table 50: Takeda Basic Information And Sales Area

Table 51: Takeda. Products Portfolio

Table 52: BioNTech SE Basic Information And Sales Area

Table 53: BioNTech SE. Products Portfolio

Table 54: Allogene Therapeutics Basic Information And Sales Area

Table 55: Allogene Therapeutics. Products Portfolio

Table 56: IMAB-I-Mab Biopharma Co.,Ltd. Basic Information And Sales Area

Table 57: IMAB-I-Mab Biopharma Co.,Ltd.. Products Portfolio

Table 58: Arcus Biosciences Basic Information And Sales Area

Table 59: Arcus Biosciences. Products Portfolio

Table 60: Gritstone Oncology Basic Information And Sales Area

Table 61: Gritstone Oncology. Products Portfolio

Table 62: Autolus Therapeutics Basic Information And Sales Area

Table 63: Autolus Therapeutics. Products Portfolio

Table 64: Rubius Therapeutics Basic Information And Sales Area

Table 65: Rubius Therapeutics. Products Portfolio

Table 66: Spectrum Pharmaceuticals Basic Information And Sales Area

Table 67: Spectrum Pharmaceuticals. Products Portfolio

Table 68: Novartis Basic Information And Sales Area

Table 69: Novartis. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Application

Table 71: Global Market Share (%) By Application (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Types

Table 73: Global Market Share (%) By Types (2032)

Table 74: Global Immuno-oncology Therapy Market Value (USD Million) By Region

Table 75: Global Immuno-oncology Therapy Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: North America Market Value (USD Million) (2025-2032) By Types

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Europe Market Value (USD Million) (2025-2032) By Types

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: South America Market Value (USD Million) (2025-2032) By Types

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Immuno-oncology Therapy Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Bristol-Myers Squibb; Roche; AstraZeneca; Pfizer; Amgen; Eli-Lilly; GlaxoSmithKline; Janssen Biotech; Sanofi; Takeda; BioNTech SE; Allogene Therapeutics; IMAB-I-Mab Biopharma Co.,Ltd.; Arcus Biosciences; Gritstone Oncology; Autolus Therapeutics; Rubius Therapeutics; Spectrum Pharmaceuticals; Novartis
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Immuno-oncology Therapy Segmentation Breakdown9 items

Application

Hospitals

Ambulatory Surgical Center

Others

Types

Monoclonal Antibodies

Immune Checkpoint Inhibitors

Immune System Modulators

Cancer Vaccines

Regional Insights

Loading chart…

Regional Drivers5 items

North America: Advanced biotech ecosystem, FDA regulatory agility, and commercialization of next-gen IO therapies.

Europe: Strong public-private partnerships, EU Horizon funding, and high patient awareness.

Asia Pacific: Surging oncology drug approvals, urbanization, and partnerships with global pharma players.

Latin America: Growing access to affordable biosimilars and rising government investments in cancer care.

Middle East & Africa: Strategic healthcare digitization, increasing incidence of lifestyle-driven cancers, and regional R&D hubs.

Competitive Landscape

Merck: Regional expansion in Asia-Pacific oncology markets

Bristol-Myers Squibb: Product launches targeting solid tumors

Roche: Strategic partnerships for combination therapies

AstraZeneca: Innovation pipeline in checkpoint inhibitors

Pfizer: Localization of manufacturing in high-growth regions

Amgen: Cost optimization through biosimilar development

Key Immuno-oncology Therapy Companies20 items

Merck

Bristol-Myers Squibb

Roche

AstraZeneca

Pfizer

Amgen

Eli-Lilly

GlaxoSmithKline

Janssen Biotech

Sanofi

Takeda

BioNTech SE

Allogene Therapeutics

IMAB-I-Mab Biopharma Co.,Ltd.

Arcus Biosciences

Gritstone Oncology

Autolus Therapeutics

Rubius Therapeutics

Spectrum Pharmaceuticals

Novartis

Market Ecosystem

Raw material/component suppliers – provide specialized reagents, cell lines, and biologics for therapy development

Biopharmaceutical manufacturers – develop and produce monoclonal antibodies, CAR-T cells, and checkpoint inhibitors

Contract research organizations (CROs) – conduct clinical trials and manage regulatory submissions

Technology providers – supply platforms for biomarker discovery, diagnostics, and digital health integration

Distributors/logistics partners – ensure cold chain compliance and global delivery of temperature-sensitive therapies

Healthcare providers – administer therapies, monitor patient responses, and report adverse events

Regulators/standards bodies – establish approval pathways and safety benchmarks for novel treatments

Recent Industry Insights

Analyst Overview

Table of Contents